Toshiyuki Tsukaguchi

CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant

Hiroshi Sakamoto, Toshiyuki Tsukaguchi, Sayuri Hiroshima et al. · Cancer Cell · 2011 · 618 citations · Full text

Molecular Pharmacology, Resistant Gatekeeper Mutant, Drug Discovery +8

Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance

Tatsushi Kodama, Toshiyuki Tsukaguchi, Miyuki Yoshida et al. · Cancer Letters · 2014 · 195 citations

Health Sciences, Medicine, Potent Antitumor Activity +9

Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)

Kazutomo Kinoshita, Kohsuke Asoh, Noriyuki Furuichi et al. · Bioorganic & Medicinal Chemistry · 2011 · 163 citations · Full text

Chemoprevention Strategy, Medicine, Anti-cancer Agent +3

Alectinib Shows Potent Antitumor Activity against <i>RET</i> -Rearranged Non–Small Cell Lung Cancer

Tatsushi Kodama, Toshiyuki Tsukaguchi, Yasuko Satoh et al. · Molecular Cancer Therapeutics · 2014 · 155 citations · Full text

The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor

Yoshito Nakanishi, Nukinori Akiyama, Toshiyuki Tsukaguchi et al. · Molecular Cancer Therapeutics · 2014 · 119 citations · Full text

Radiation Oncology, Fgf Receptors, Novel Therapy +13